GMP to review 172 drug companies without advanced notification.

Published: 2006-03-24 06:58:00

Updated: 2006-03-24 06:58:00

The KFDA announced to review the GMP for 172 drug companies who were rated at an ordinary grade or lower starting from March 17, especially focusing on their facilities and quality controls.

The rating review was determined without any prior notification to them unlike the KFDA's conventional ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK